EU plans risk reduction steps for Servier, Amgen heart drug

LONDON (Reuters) – Experts at the European Medicines Agency have recommended measures to reduce the risks associated with a drug from private French company Servier that helps lower the heart rate and which was licensed to U.S. group Amgen last year. Ivabradine is not currently approved in the United States but it is sold in Europe for treating stable angina, or chest pain due to obstruction of heart arteries, and for heart failure, when the heart fails to pump blood effectively. …
Go to Source

U.N.’s Zeid accuses Sri Lanka of trying to sabotage war crimes probe

By Tom Miles and Shihar Aneez GENEVA/COLOMBO (Reuters) – The U.N. High Commissioner for Human Rights on Friday accused Sri Lanka of trying to “sabotage” a war crimes inquiry, creating a “wall of fear” to prevent witnesses from giving evidence. The U.N. Human Rights Council set up the inquiry in March to investigate crimes allegedly committed by both government forces and Tamil rebels during the final stages of a 26-year conflict that ended in 2009. …
Go to Source

Humana third-quarter profit falls on investments, drug costs

(Reuters) – U.S. health insurer Humana Inc on Friday reported a lower third-quarter profit that missed Wall Street estimates as it paid for costly hepatitis C treatments and invested in the Obamacare health insurance exchanges and state-based health contracts. For 2015, the company said earnings would rise as it spends less on those state-based health contracts and its large Medicare business benefits from a new government ratings system that should offset planned cuts to payments in the program for the elderly and disabled. …
Go to Source

1 97 98 99 100 101 1,024